A Phase 1b Presurgical Window Study to Evaluate Immune Biomarker Modulation in Response to Motolimod and Nivolumab in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)

SCCHNs are a complex and difficult-to-treat group of aggressive cancers. Surgery and radiotherapy remain the primary treatments for locoregional SCCHN; however, they are associated with significant morbidity and high recurrence rates. Although immune checkpoint inhibitors such as the anti-PD-1 antibody nivolumab are active in SCCHN, strategies to improve response rate and durability are needed. The development of more effective therapies is hindered by the immunosuppressive nature of these tumors.

Source: International Journal of Radiation Oncology * Biology * Physics - March 12, 2020 Category: Radiology Authors: D. Adkins, E. Cohen, L. Nabell, D. Zandberg, M. Old, D. Cognetti, D. Blair, X. Wei, A. Wells, A. Patel, T. Foy, K. Hege, R.L. Ferris Tags: Immunology and Immunotherapy Source Type: research